NUTRAFUELS, INC.

OTC MARKETS
OTC PINK DISCLOSURE STATEMENT
FOR THE QUARTER ENDED SEPTEMBER 30, 2016

Name of the issuer and its predecessors (if any)

NutraFuels, Inc, a Florida corporation ("us", "we" or "our") was formed as a limited liability company in the state of Florida on April 1, 2010, to engage in the development and distribution of nutritional and dietary oral spray products. On December 3, 2012, we converted from a Limited Liability Company to a Florida Corporation.

We have no other predecessors.

Address of the issuer's principal executive offices

The address of our principal executive offices is:
NutraFuels, Inc.
6601 Lyons Road, L6
Coconut Creek Florida 33073
Tel: 888-509-8901
Fax: 754-227-5970
Website(s): www.nutraspray.com

Our Chief Executive Officer, Edgar Ward is responsible for the company's investor relation's activity. We do not employ an investor relations firm.

Security Information

The trading symbol of our common stock is NTFU.

The CUSIP number for our common shares is 67091B104.

We have two classes of stock outstanding, which are our common shares, $0.0001 par value per share and Series A Preferred Shares $0.0001 par value per share.

There are 69 record holders of our common shares.

We are authorized to issue 499,990,000 common shares and 10,000,000 shares of Preferred Stock of which 31,518,628 common shares and 1,000 preferred shares are outstanding as of November 28, 2016.

We presently have 8,318,609 unrestricted and 23,200,019 restricted common shares outstanding.

The Series A Preferred Stock entitle the holder to 500,000 votes per share or an aggregate of 500,000,000 votes on all matters submitted to our stockholders. The Series A Preferred shares are not convertible into our common stock.

Our transfer agent is VStock Transfer LLC located at 77 Spruce Street, Suite 201, Cedarhurst, NY 11516. Its telephone number is 212-828-8436 and its website is located at http://www.vstocktransfer.com.

VStock Transfer is registered as a transfer agent with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended.

There are no restrictions on the transfer of our common shares other than those imposed under federal and state securities laws.

We have never been subject to a trading suspension order issued by the Securities & Exchange Commission.

We have not engaged in a stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization since our inception, and have no present plans to engage in a stock split.

Issuance History

In the two years, prior to the filing of this Information and Disclosure Statement, we offered and sold securities below.

- None of the issuances involved underwriters, underwriting discounts or commissions and all proceeds were delivered to us.
- We relied upon Sections 4(2) of the Securities Act, and Rule 506 of the Securities Act of 1933, as amended for the offer and sale of the securities.
- All securities were issued with restrictive legends.

Convertible Notes Sold for Cash Consideration

Name	***Date of Investment***	***Amount of investment***	***Principal & Interest Currently Outstanding as of 9/30/16***	***Aggregate Number of Shares Issuable Upon Conversion as of 9/30/16***	***Conversion Price Per Share***	***Maturity Date***	***Interest Rate***	***Shares Issued as Additional Consideration for Note***
John Hampton	August 27, 2014	***$50,000***	***60,473***	***60,473***	***$1.00***	***July 15, 2017***	***10%***	***50,000***
John Hampton	October 3, 2014	***$60,000***	***71,950***	***71,950***	***$1.00***	***July 15, 2017***	***10%***	***60,000***
Dennis Poland(1)	December 2, 2014	***$30,000***	***30,000***	***0***	***n/a***	***July 15, 2017***	***n/a***	***30,000***
Dennis Poland(1)	February 14, 2014	***$25,000***	***$25,000***	***0***	***n/a***	***July 15, 2017***	***n/a***	***50,000***
Craig Hetherington	August 26, 2013	$200,000	***282,917***	***282,917***	***$1.00***	July 15, 2017	***15%***	**---**
James O'Leary	February 20, 2015	$25,000	***$25,000***	***100,000***	***$0.25***	February 20, 2017	***n/a***	***25,000***
James R. Stuart(1)	August 14, 2015	***$25,000***	***27,826***	***27,826***	***$1.00***	December 1, 2016	***10%***	**---**
Donald Brennick	August 26, 2015	***$25,000***	***27,743***	***27,743***	***$1.00***	August 26, 2016	***10%***	**---**
Craig Hetherington	June 7, 2013	$100,000	132,361	132,361	$1.00	July 15, 2017	10%	---

Craig Hetherington	March 26, 2014	$290,000	399,717	399,717	$1.00	July 15, 2017	15%	---
Craig Hetherington	June 23, 2014	$30,000	36,6825	36,825	$1.00	July 15, 2017	10%	---
Ann Noble	August 14, 2015	$0	2,500	25,000	$.10	Principal converted		-
Barbara Ludwig	August 14, 2015	$0	2,000	20,000	$.10	Principal Converted		-
William Ferri	April 14, 2015	$250,000	286,250	286,250	$1.00	July 15, 2017		250,000
Richard Scott Lohan	April 19, 2016	$38,000	0	0	n/a	repaid		100,000
Richard Scott Lohan	June 22, 2016	$27,000	27,735	110,940	$.25	Oct. 15th 2016		70,000
Jim Laurain	June 9, 2016	$20,000	20,628	82,512	$.25	Sept. 30th 2016		20,000
Michael Farr	June 23, 2016	$0	2,021	8,083	$.25	repaid		70,000
Jim Laurain	July 26, 2016	$20,000	20,367	81,468	$.25	Oct. 17th 2016		15,000
Jerry Thompson	July 6, 2016	$15,000	15,342	61,368	$.25	Sept. 30th 2016		15,000
Michael Farr(2)	August 29, 2016	$35,000	35,301	141,206	$0.25	October 13, 2016		100,000
Michael Farr	September 21, 2016	$40,000	40,100	160,400	$0.25	November 20, 2016		100,000

(1) Converted subsequent to September 30, 2016
(2) Repaid subsequent to September 30, 2016

Shares Issued Upon Conversion of Notes

On August, 24, 2016, Ann Noble converted principal in the amount of $25,000 pursuant to under a August 14, 2015 convertible note into our common shares at the price of $.10 per share or an aggregate of 250,000 shares.

On August, 14, 2016, Barbara Ludwig converted principal due in the amount of $20,000 pursuant to an August 14, 2015 convertible note into our common shares at the price of .10 per share or an aggregate of 200,000 shares.

Shares Issued for Cash Consideration

On April 3, 2015, we sold 30,000 shares of our common stock to Barbara Ludwig at the price of $.20 per share

or an aggregate of $6,000.

On July 25, 2016, we sold 150,000 shares of our common stock to John Berning at the price of $.10 per share or an aggregate of $15,000.

On July 27, 2016, we sold 500,000 shares of our common stock to Paul Botts at the price of $.10 per share or an aggregate of $50,000.

From June 1, 2016, to August 18, 2016, we sold 1,400,000 shares of our common stock to Dominant Holdings LLC, a Massachusetts limited liability company controlled by Kelly Benson at the price of $.10 per share or an aggregate of $140,000.

Units with Options & Cashless Options/Warrants Issued for Cash Consideration

On February, 17, 2015 we sold 25,000 units to Jerry O'Leary at the price of $1.00 per unit or an aggregate of $25,000. Each unit contains: (i) 25,000 shares of our common stock; (ii) 2-year options to purchase 25,000 shares of our common stock at $0.20, and (iii) a 2-year convertible Promissory Note in the amount of $25,000. The note is non- interest bearing and is convertible into shares of our common stock at the higher of (a) twenty-five cents ($.25) or fifty percent (50%) of the average closing price of our common stock as reported by the OTC Markets for the 10 trading days prior to the date of conversion. The options expire on February 17, 2017.

On April 21, 2015 we sold 250,000 units to William Ferri in exchange for $250,000. Each one (1) unit contains: (i) 250,000 shares of common stock; (ii) 250,000 options and (iii) a promissory note in the amount of $250,000 which matures in April 2017. The note bears interest at the rate of $10%. The options are exercisable at the higher of twenty-five cents ($.25) or fifty percent (50%) of the average closing price of the Company's shares as reported by the OTC Markets for the 10 trading days prior to the day of conversion. The options expire on April 21, 2017.

On October 19, 2015, we sold 500,000 units to Jerry F. Thompson at the price of $0.10 per unit or an aggregate of $50,000. Each unit consists of one (1) share of common stock and one (1) warrant to purchase one (1) share of common stock at the price of $0.50 at any time until October 19, 2016. On November 2, 2015 we issued Jerry F. Thompson cashless warrants for 50,000 shares of common stock which may be exercised at any time until October 19, 2017.

Units with Warrants Exercisable at $.50 Sold for Cash Consideration

From June 4, 2015 through May 18, 2016, we sold the Units below. Each unit consists of one (1) share of common stock and one (1) warrant to purchase one (1) share of common stock at the price of $0.50 at any time until the two- year anniversary of the date of the investment.

Name	Date	Aggregate Investment	Number of Units Purchased ($.10 Per Unit)	Exercise Price Of Warrant	Expiration Date
G&C Investment Corp, a Florida corporation controlled by Jorge Garrido	June 4, 2015	$10,000	100,000	$.10	June 4, 2017
Paul Paternoster	August 31, 2015	$40,000	400,000	$.10	August 31, 2017

Scott Lohan	September 21, 2015	$30,000	300,000	$.10	September 21, 2017
Tom & Carol Perrine	October 13, 2015	$10,000	100,000	$.50	October 13, 2017
James Laurain	October 22, 2015	$10,000	100,000	$.50	October 22, 2017
Alan Maurer	October 22, 2015	$10,200	102,000	$.50	October 22, 2017
Barclay Armitage	November 5, 2015	$5,000	50,000	$.50	November 5, 2017
Michael Ward	November 17, 2015	$5,000	50,000	$.50	November 17, 2017
James Laurain	November 25, 2015	$20,00	200,000	$.50	November 25, 2017
David Knudtson	December 7, 2015	$5,000	50,000	$.50	December 7, 2017
James Laurain	December 10, 2015	$15,000	150,000	$.10	December 10, 2017
William Rodriguez	December 15, 2015	$20,000	200,000	$.50	December 15, 2017
Nathaniel Rodriguez	December 15, 2015	$5,000	50,000	$.50	December 15, 2017
Jerry F. Thompson	December 16, 2015	$25,000	250,000	$.50	December 16, 2017
Jerry F. Thompson	December 16, 2015	$25,000	250,000	$.50	December 16, 2017
Barclay Armitage	January 8, 2016	$7,500	75,000	$.50	January 8, 2018
Jerry F. Thompson	January 21, 2016	$15,000	150,000	$.50	January 21, 2018
Michael Farr	January 28, 2016	$25,000	250,000	$.50	January 28, 2018
Jerry F. Thompson	February 5, 2016	$20,000	200,000	$.50	February 5, 2018
Kerry McDonald	February 19, 2016	$7,500	75,000	$.50	February 19, 2018
Jerry F. Thompson	February 23, 2016	$6,500	65,000	$.50	February 23, 2018
Thomas Jacobsen	February 23, 2016	$25,000	250,000	$.50	February 23, 2018
James Laurain	March 9, 2016	$5,000	50,000	$.50	March 9, 2018
Jerry F. Thompson	March 18, 2016	$15,000	150,000	$.50	March 18, 2018
James Laurain	March 18, 2016	$45,000	450,000	$.50	March 18, 2018
Anthony J. Monteleone	May 2, 2016	$20,000	200,000	$.50	May 2, 2018
Leon English	May 6, 2016	$10,000	100,000	$.50	May 6, 2018
James Laurain	May 18, 2016	$5,000	50,000	$.50	May 18, 2018

Securities Issued for Services Rendered

On October 14, 2014, we issued 60,000 shares of our common stock to Uptick Capital, LLC, a Connecticut limited liability company controlled by Ari Blaine and Simeon Wohlberg for services rendered to us. We valued these shares at $0.80 per share. On March 5, 2015 we issued 60,000 shares of our common stock to Uptick Capital, LLC for services rendered to us. We valued these shares at $0.60 per share.

On April 14, 2015, we issued 100,000 common shares to Benchmark Advisory Partners, LLC, a California limited liability company controlled by Timothy Connor for services rendered. We valued these shares at $.20 per share or an aggregate of $20,000.

On July 18, 2015, we issued 150,000 common shares to WT Consulting Group, LLC, a Florida limited liability company controlled by William Hirschy for consulting services rendered. We valued these shares at $0.25 per share or an aggregate of $37,500.

On October 1, 2015, we issued 30,000 of our common stock to Peter Cianci in exchange for services rendered. We valued these shares at the price of $ .40 per share or an aggregate of $12,000.

On October 1, 2015, we issued 40,000 shares to Five Star Labs, LLC, a Florida limited liability company controlled by Eric Caprarese for services rendered. We valued these shares at $0.40 per share or an aggregate of $40,000.00.

On August 15, 2015, we granted Sullivan Media Group cashless warrants in exchange for services rendered to us.

The warrants may be exercised for a period of two years after the grant date as follows:

August 15th 2015	1,791,369	Mitsukp Takezawa
August 15th 2015	1,791,369	Ed and Patricia Sullivan
August 15th 2015	895,684	Michael Perog

On June 9, 2016, we issued Josh Zwagil 244,514 shares for new business development. We valued these shares at $0.11 per share, or an aggregate of $26,896.54.

Financial Statements

Financial statements for our two most recent fiscal year end periods were posted on the OTC Markets website on June 28, 2016. The financial statements include our balance sheet, statement of income, statement of changes in stockholders equity, statement of cash flows, and financial notes. Financial statements for our most recent quarter end period was posted on the OTC Markets website on December 2, 2016. The financial statements include our balance sheet, statement of income, statement of changes in stockholders equity, statement of cash flows, and financial notes.

Describe the Issuer's Business, Products and Services

Our SIC code is 5411.

Organization

We were formed as a limited liability company in the state of Florida on April 1, 2010 to engage in the development and distribution of nutritional and dietary oral spray products. On December 3, 2012, we converted from a Limited Liability Company to a Florida Corporation.

Our principal executive office is located at 6601 Lyons Road, Suite L-6, Coconut Creek, Florida 33073, and our telephone number is 888-509-8901.

We have not been involved in a bankruptcy receivership or similar proceeding. Additionally, we have not been involved in a reclassification, merger, consolidation, purchase or sale of a significant amount of assets not in the ordinary course of business.

For the nine months ended September 30, 2016 and years ended December 31, 2015, and 2014, we received $419,000, $220,300 and $680,000, respectively from the sale of our common stock. For the nine months ended September 30, 2016 and the years ended December 31, 2015 and 2014, we received $247,000 $582,500 and $565,000, respectively from the issuance of Promissory Notes.

For the nine months ended September 30, 2016, and the years ended 2015 and 2014, our revenues were $260,471, $193,998 and $62,274, respectively. We incurred net losses of $657,475, $2,101,061 and $2,075,720 for the nine months ended September 30, 2016, and the years ended December 31, 2015 and 2014, respectively.

Our Business

We manufacture and distribute oral spray nutritional and dietary products. Our products are primarily sold through two private label distributors.

Our oral spray products are designed to provide faster and more efficient absorption than capsules or liquid

formulas. Each product we offer is based upon the research of Edgar Ward, our Chief Executive Officer, President and sole Director, and in-house chemist. Our products are and in the future will continue to be identified by Mr. Ward based upon suggestions from our customers, and from industry and market research he conducts on an ongoing basis. We do not employ medical professionals and our management does not have experience in the healthcare industry or in the treatment of disease. Our products have not been confirmed in any respect by the U.S. Food and Drug Administration or any other governmental agency, and may not produce the results intended.

All of our products are manufactured at our facility in Coconut Creek, Florida. We obtain all raw materials and ingredients for our products from third party suppliers. For all orders, we manufacture, package, label and ship the product to the customer.

Our website http://www.shopnutrafuels.com allows retail customers to purchase our products on the internet. Our website http://www.nutrafuels.com is used by our wholesale customers to place orders.

Our distribution strategy includes selling to retailers, distributors, private label customers and consumers through our retail website.

Our Products

During 2014, we developed three (3) new spray products and expanded our product offerings adding two new products, Headache and Pain Spray and Hair, Skin and Nails Spray. We also made modifications to our NutraFuels Weight Loss Spray, which now contains Garcinia Cambogia.



Our products are as follows:

NutraFuels Sleep Spray

Our Sleep Spray contains Melatonin, GABA and Valerian Root. NutraFuels Sleep Spray is designed to support a healthy sleep cycle and improve the quality of restful sleep. The retail price of our Sleep Spray is $9.95 per .25 (¼) ounce.

NutraFuels Energy Spray

Our Energize Spray contains B complex Vitamins, B-12. NutraFuels Energize Spray is designed to increase energy and restore vigor and vitality. The retail price of our Energize Spray is $9.95 per .25 (¼) ounce.

NutraFuels Garcinia Cambogia Spray

Our Appetite and Weight management Spray contains Garcinia Cambogia. Our NutraFuels Garcinia Cambogia Spray is designed to suppress the appetite and boost metabolism. The retail price of our Weight-Loss Spray is $17.95 per 3 pack of 3 .25 (¼) ounce bottles.

NutraFuels Headache & Pain Spray

Our Headache and Pain Spray contains Turmacin, a natural anti-inflammatory. Our NutraFuels Headache and Pain Spray is designed to relieve headaches and pain. The retail price of our Headache and Pain Spray is $9.95 per .25 (¼) ounce. We plan to launch this product in August 2016.

NutraFuels Hair, Skin & Nails Spray

Our Hair, Skin and Nails Spray contains Biotin, MSM, and Collagen. Our NutraFuels Hair, Skin and Nails Spray is designed to nourish and encourage hair, skin and nail growth. The retail price of our Hair, Skin and Nails Spray is $9.95 per .25 (¼) ounce.

Order Processing

We package and label all products we manufacture. We store inventory at our manufacturing facility. Upon receiving orders for products not in inventory, we manufacture, package and label the product. We ship the product ordered within 30 days to retail customers and within 4 weeks to our distributors and private label customers. All orders are shipped by freight delivery.

Distributors

We receive approximately 98 % of our revenues from the sales made by our two private label distributors. As a result, our revenues are highly concentrated. Should either of these two distributors decrease or cease-ordering products from us, our revenues and results of operations will be negatively affected.

Website Sales

Our retail website is www.ShopNutraFuels.com. Website orders are paid for upon order. Website orders accounted for less than 2% of our revenues for the year ending December 31, 2015 and for the nine months ended September

30, 2016.

Product Quality

In developing our products, we require:

- ingredients that are supported with a certificate of analysis, publicly available scientific research and references which our Chief Executive Officer reviewed with a chemist who developed our final products;

- ingredients that are combined so that their effectiveness is not impaired;
- ingredients that are in dosage levels that fall within tolerable upper intake levels established for healthy people by the Institute of Medicine of the National Academies;
- products that do not contain any substances banned by major sporting organizations such as the World Anti-Doping Agent, or WADA, NFL or MLB, or adulterated ingredients such as ephedra, androstenedione, aspartame, steroids or human growth hormones; and
- formulations that have a minimum one-year shelf life.

Marketing Strategy

Our core marketing strategy is to market our brand to those seeking to improve the quality of life through dietary supplementation. We believe that our marketing mix of web, TV, print, radio, billboards and in store event promotions, providing coupons along with sample products for our retail resellers to use, is an optimal strategy to increase sales.

Return and Refund Policy

We will exchange any product found to be defective. A written exchange request must be submitted when a customer returns defective or damaged products. Purchasers can apply for a refund in full amount of purchased products within 10 days of purchase. If the purchasers are not satisfied with our products for any reason, they can return products and request for an exchange. All shipping fees for product exchanges or returns must be paid by the purchaser. Historically, product returns as a percentage of our net sales have been nominal.

Patents and Trademarks

We received federal trademark registration for the expression "Spray your way to a healthier day!" that we use or intend to use to distinguish ourselves from others. All trademark registrations are protected for an initial period of five years and then are renewable after five years, if still in use, and every 10 years thereafter.

We hold the following trade names from the U.S. Patent and Trademark office:

- OralPro NutraSpray
- NutraSpray
- NRG-X Spray
- Micro-Blast Body Slim
- Micro-Blast
- Body Slim
- Spray your way to a healthier day!

Employees

Our full-time employees are as follows:

- Our Chief Executive Officer, President and sole Director, Edgar Ward oversees our day to day operations;
- One (1) supervisor of our manufacturing facility;
- Four (4) full time employees who assist in our manufacturing facility;
- One (1) Chemist;
- One (1) Secretary; and
- One (1) Administrative Assistant.

Neil Catania, our Vice President works closely with Edgar Ward and provides us with approximately 40 hours per month of services.

None of our employees are employed under a collective bargaining agreement. We believe we have an excellent relationship with our employees and independent contractors.

Manufacturing

Our manufacturing process generally consists of the following operations: (i) sourcing ingredients for products, (ii) warehousing raw ingredients, (iii) measuring ingredients for inclusion in products, and (iv) blending using automatic equipment. The next step, bottling and packaging, involves filling, capping, coding, labeling and placing the product in packaging with appropriate tamper-evident features then sending the packaged product to our customers.

We manufacture, package, label and store our products at our facility in Coconut Creek, Florida. We manufacture 100% of our products. By manufacturing our own products, we believe that we maintain better control over product quality and availability while also reducing production costs.

The FDA requires companies manufacturing homeopathic medicines to have their facilities certified as Good Manufacturing Practices ("GMPs"). Our manufacturing facility has been fully compliant with its GMP certification. Our quality control program seeks to ensure the superior quality of our products and that they are manufactured in accordance with current GMP. Our processing methods are monitored closely to ensure that only quality ingredients are used and to ensure product purity. Periodically, we retain the services of outside GMP audit firms to assist in our efforts to comply with GMPs. In 2013, we used the services of ASI Food Safety Consultants, Inc., a GMP audit firm to assist us with our GMP compliance.

Sources and Availability of Raw Materials

Raw materials used by us are available from a variety of suppliers. We maintain a good relationship with our suppliers and do not anticipate that any of our suppliers will terminate their relationship with us in the near term. We have ongoing relationships with secondary and tertiary suppliers. In the event, we are unable to obtain any of our raw materials from our suppliers; we believe that we could obtain alternative sources of any raw materials from other suppliers. We do not have contracts with our suppliers and we order our raw materials on an as-needed basis. We have not experienced any material adverse effects on our business as a result of shortages of raw materials or packaging materials used in the manufacturing of our products. An unexpected interruption or a shortage in supply of raw materials could adversely affect our business derived from these products.

Backlog of Orders

We have no backlog of orders.

Seasonal Aspect of our Business

None of our products are affected by seasonal factors.

Status of any Publicly Announced New Product or Service

We do not have any publicly announced new product or service.

Competitive Business Conditions

The nutritional and dietary supplement industries are highly competitive. Nutritional supplements include vitamins, minerals, dietary supplements, herbs, botanicals and compounds derived therefrom. Numerous manufacturers and distributors compete with us for customers throughout the United States in the packaged nutritional supplement industry selling products to retailers such as mass merchandisers, drug store chains, independent pharmacies and health food stores. We are also vulnerable to competition from companies that can purchase similar products to our products and private label them with their own brand name.

Many of our indirect competitors are substantially larger, have more experience than us, have longer operating histories, and have materially greater financial and other resources than us.

Costs and Effects of Compliance with Environmental Laws

We are in a business that involves the use of raw materials in a manufacturing process, however, it is unlikely that such materials are likely to result in the violation of any existing environmental rules and/or regulations. Further, we do not own any real property that could lead to liability as a landowner. Therefore, we do not anticipate that there will be any material costs associated with compliance with environmental laws and regulations.

Government Approvals

We are not required to obtain governmental approval of our products.

Product Liability

We have product liability insurance for our manufacturing activities and products in the amount of $5,000,000. Product liability claims may result in significant legal costs related to our defense of such actions if the amounts exceed our product liability insurance coverage. The design, development, and manufacture of products for human consumption involves an inherent risk of product liability claims and corresponding damage to our brand name reputation, including claims of product failure or harm caused by our products. As such, any product liability claim could adversely affect our business.

Government Regulation

The formulation, manufacturing, packaging, labeling, advertising, distribution and sale (hereafter, "sale" or "sold" may be used to signify all of these activities) of our products are subject to regulation by one or more federal agencies, principally the Food and Drug Administration ("FDA") and the Federal Trade Commission ("FTC"), and to a lesser extent the Consumer Product Safety Commission ("CPSC"), the United States Department of Agriculture ("USDA")and the Environmental Protection Agency ("EPA"). Our activities are also regulated by various governmental agencies for the states and localities in which our products are sold, as well as by governmental agencies in certain countries outside the United States in which our products are sold. Among other matters, regulation by the FDA and FTC are concerned with product safety and claims made with respect to a product's ability to provide health-related benefits. Specifically, the FDA, under the Federal Food, Drug, and Cosmetic Act

("FDCA"), regulates the formulation, manufacturing, packaging, labeling, distribution and sale of food, including dietary supplements, and over-the-counter drugs. The FTC regulates the advertising of these products. The National Advertising Division ("NAD") of the Council of Better Business Bureaus oversees an industry-sponsored, self-regulatory system that permits competitors to resolve disputes over advertising claims. The NAD has no enforcement authority of its own, but may refer matters that appear to violate the Federal Trade Commission Act or the FDCA to the FTC or the FDA for further action, as appropriate.

Federal agencies, primarily the FDA and the FTC, have a variety of procedures and enforcement remedies available to them, including initiating investigations, issuing warning letters and cease-and-desist orders, requiring corrective labeling or advertising, requiring consumer redress (for example, requiring that a company offer to repurchase products previously sold to consumers), seeking injunctive relief or product seizures, imposing civil penalties, or commencing criminal prosecution. In addition, certain state agencies have similar authority. These federal and state agencies have in the past used these remedies in regulating participants in the food, dietary supplement and over-the-counter drug industries, including the imposition of civil penalties in the millions of dollars against a few industry participants.

The Dietary Supplement Health and Education Act ("DSHEA") was enacted in 1994, amending the FDCA. We believe DSHEA is generally favorable to consumers and to the dietary supplement industry. DSHEA establishes a statutory class of "dietary supplements," which includes vitamins, minerals, herbs, amino acids and other dietary ingredients for human use to supplement the diet. Dietary ingredients marketed in the United States before October 15, 1994 may be marketed without the submission of a "new dietary ingredient" ("NDI") premarket notification to the FDA. Dietary ingredients not marketed in the United States before October 15, 1994 may require the submission, at least 75 days before marketing, of an NDI notification containing information establishing that the ingredient is reasonably expected to be safe for its intended use. Among other things, DSHEA prevents the FDA from regulating dietary ingredients in dietary supplements as "food additives" and allows the use of statements of nutritional support on product labels and in labeling. The FDA has issued final regulations under DSHEA and has issued draft guidance on NDI notification requirements. Further guidance and regulations are expected. Several bills to amend DSHEA in ways that would make this law less favorable to consumers and industry have been proposed in Congress.

The Nutrition Labeling and Education Act of 1990 ("NLEA") amended the FDCA to establish additional requirements for ingredient and nutrition labeling and labeling claims for foods. If the NLEA labeling requirements change at a future time, we may need to revise our product labeling. Most of our products are classified as dietary supplements.

The FDA issued a Final Rule on GMPs for dietary supplements on June 22, 2007. The GMPs cover manufacturers and holders of finished dietary supplement products, including dietary supplement products manufactured outside the United States that are imported for sale into the United States. Among other things, the new GMPs: (a) require identity testing on all incoming dietary ingredients, (b) call for a "scientifically valid system" for ensuring finished products meet all specifications, (c) include requirements related to process controls, including statistical sampling of finished batches for testing and requirements for written procedures and (d) require extensive recordkeeping.

We have reviewed the GMPs and have taken steps to ensure compliance. While we believe we are in compliance, there can be no assurance that our operations or those of our suppliers will be in compliance in all respects at all times. Additionally, there is a potential risk of increased audits as the FDA and other regulators seek to ensure compliance with the GMP's.

On December 22, 2006, Congress passed the Dietary Supplement and Nonprescription Drug Consumer Protection Act, which went into effect on December 22, 2007. The law requires, among other things, that companies that manufacture or distribute nonprescription drugs or dietary supplements report serious adverse events allegedly associated with their products to the FDA and institute recordkeeping requirements for all adverse events (serious and non-serious). There is a risk that consumers, the press and government regulators could misinterpret reported

serious adverse events as evidence of causation by the ingredient or product complained of, which could lead to additional regulations, banned ingredients or products, increased insurance costs and a potential increase in product liability litigation, among other things.

The Consumer Product Safety Improvement Act of 2008 ("CPSIA") primarily addresses children's product safety but also improves the administrative process of the CPSC. Among other things, the CPSIA requires testing and certification of certain products and enhances the CPSC's authority to order recalls.

The FDA Food Safety Modernization Act ("FSMA"), enacted January 4, 2011, amended the FDCA to significantly enhance the FDA's authority over various aspects of food regulation. The FSMA granted the FDA mandatory recall authority when the FDA determines if there is reasonable probability that a food is adulterated or misbranded and that the use of, or exposure to, the food will cause serious adverse health consequences or death to humans or animals. Other changes include the FDA's expanded access to records; the authority to suspend food facility registrations and require high risk imported food to be accompanied by a certification; stronger authority to administratively detain food; the authority to refuse admission of an imported food if it is from a foreign establishment to which a U.S. inspector is refused entry for an inspection; and the requirement that importers verify that the foods they import meet domestic standards.

One of the FSMA's more significant changes is the requirement of hazard analysis and risk-based preventive controls ("HARBPC") for all food facilities required to register with the FDA, except dietary supplement facilities in compliance with both GMPs and the serious adverse event reporting requirements. Although dietary supplement facilities are exempt from the HARBPC requirements, dietary ingredient facilities might not qualify for the exemption. The HARBPC requirements, which the FDA has yet to propose, are expected to be onerous because facilities will have to develop and implement preventive controls to assure that identified hazards are significantly minimized or prevented, monitor the effectiveness of the preventive controls and maintain numerous records related to the HARBPC. The HARBPC requirements may increase the costs of dietary ingredients and/or affect our ability to obtain dietary ingredients.

As required by Section 113(b) of the FSMA, the FDA published in July 2011 a draft guidance document clarifying when the FDA believes a dietary ingredient is an NDI, when a manufacturer or distributor must submit an NDI premarket notification to the FDA, the evidence necessary to document the safety of an NDI and the methods for establishing the identity of an NDI. The draft guidance, if implemented as proposed, could have a material impact on our operations. Although our industry has strongly objected to several aspects of the draft guidance, it is unclear whether the FDA will make changes to the final guidance. In addition, it is possible that the FDA will begin taking enforcement actions consistent with the interpretations in the draft guidance before issuing a final version.

The new FSMA requirements, as well as the FDA enforcement of the NDI guidance as written, could require us to incur additional expenses, which could be significant, and negatively impact our business in several ways, including, but not limited to, the detention and refusal of admission of imported products, the injunction of manufacturing of any dietary ingredients or dietary supplements until the FDA determines that such ingredients or products are in compliance and the potential imposition of fees for re-inspection of noncompliant facilities. Each of these events would increase our liability and could have a material adverse effect on our financial condition, results of operations or cash flows.

The FTC and the FDA have pursued a coordinated effort to challenge what they consider to be unsubstantiated and unsafe weight-loss products, and have also coordinated enforcement against dietary supplement claims in other areas, including children's products. Their efforts to date have focused on manufacturers and marketers as well as media outlets, and have resulted in a significant number of investigations and enforcement actions, some resulting in civil penalties of several million dollars under the Federal Trade Commission Act. We expect that the FTC and the FDA will continue to focus on health-related claims for dietary supplements and foods, and our products could be

the subject of an FTC/FDA inquiry.

RISK FACTORS

In addition to the other information provided in this Information and Disclosure Statement, you should carefully consider the following risk factors in evaluating our business before purchasing any of our common stock.

Risks Related to Our Financial Condition

We are dependent on the sale of our securities to fund our operations.

For the nine months ended September 30, 2016 and years ended 2015 and 2014, our revenues were $260,471, $193,998 and $62,274, respectively. We will need to obtain additional financing in order to complete our business plan because we currently do not have any income. We do not have any arrangements for outside financing. We are dependent on the sale of our securities to implement our business plan and fund our operations. There is no assurance we will be able to obtain future funding for our operations from the sale of our securities. The future issuance of our securities will result in substantial dilution in the percentage of our common stock held by our then existing stockholders, and would likely have an adverse effect on any trading market for our common stock. Obtaining financing would be subject to a number of factors, including investor acceptance. These factors may adversely affect the timing, amount, terms, or conditions of any financing that we may obtain or make any additional financing unavailable to us. If we do not obtain additional financing our business will fail.

We are an early stage company with little or no historical performance for you to base an investment decision upon, and we may never become profitable.

We have limited historical performance upon which you may evaluate our prospects for achieving our business objectives and becoming profitable in light of the risks, difficulties and uncertainties frequently encountered by early stage companies such as us. Accordingly, before investing in our common stock, you should consider the challenges, expenses and difficulties that we will face as an early stage company, and whether we will ever become profitable.

If we are unable to generate sufficient revenues for our operating expenses we will need financing, which we may be unable to obtain; should we fail to obtain sufficient financing, our potential revenues will be negatively impacted.

For the nine months ended September 30, 2016, and years ended December 31, 2015, and 2014, we received $2419,000; $220,300 and $680,000, respectively from the sale of our common stock. For the snine months ended September 30, 2016 and the years ended December 31, 2015 and 2014, we received $247,000, $582,500 and $565,000, respectively from the issuance of Promissory Notes. For the nine months ended September 30, 2016 and years ended 2015 and 2014, our revenues were $260,471, $193,998 and $62,274, respectively. Our operating expenses are presently approximately $45,000 per month. As of September 30, 2016, we had $60,000 of cash and cash equivalents for our operational needs. Until we generate material operating revenues, we require additional debt or equity funding to continue our operations. We intend to raise additional funds from an offering of our stock in the future; however, this offering may never occur, or if it occurs, we may be unable to raise the required funding. We do not have any plans or specific agreements for new sources of funding and we have no agreements for financing in place.

We are highly leveraged and our substantial leverage basis will adversely affect our ability to raise additional capital to fund our operations and limit our ability to react to changes in the economy or our industry and prevent us from meeting our obligations under our indebtedness.

We are highly leveraged. As of September 30, 2016 and December 31, 2015, our total liabilities were $2,732,969 and $2,391,382. Our high degree of leverage could have important consequences for our investors, including: making it more difficult for us to make payments on indebtedness; increasing our vulnerability to general economic and industry conditions; requiring a substantial portion of cash flow from operations to be dedicated to the payment of principal and interest on indebtedness when our indebtedness becomes due. This reduces our ability to use our cash flow to fund our operations, capital expenditures and future business opportunities; limiting our ability and the ability of our subsidiaries to obtain additional financing for working capital, capital expenditures, product development, debt service requirements, acquisitions and general corporate or other purposes; and limiting our ability to adjust to changing market conditions and placing us at a competitive disadvantage compared to our competitors who are less highly leveraged. We may be able to incur substantial additional indebtedness in the future, subject to the restrictions contained in our indentures relating to outstanding convertible Promissory Notes. If new indebtedness is added to our current debt levels, the related risks that we face could increase.

Risks Related to Our Business

If the products we sell do not have the healthful effects intended, our business may suffer.

In general, our products contain food, nutritional supplements which are classified in the United States as "dietary supplements" which do not currently require approval from the FDA or other regulatory agencies prior to sale. Many of our products contain innovative ingredients or combinations of ingredients. There is little long-term experience with human or other animal consumption of certain of these ingredients or combinations thereof in concentrated form. Our products could have certain side effects if not taken as directed or if taken by a consumer that has certain medical conditions. Furthermore, there can be no assurance that any of the products, even when used as directed, will have the effects intended or will not have harmful side effects.

We may be exposed to material product liability claims, which could increase our costs and adversely affect our reputation and business.

As a manufacturer and distributor of products intended for human consumption, we are subject to product liability claims if the use of our products for others is alleged to have resulted in injury. Our products consist of vitamins, minerals, herbs and other ingredients that are classified as dietary and nutrition supplements and in most cases are not subject to pre-market regulatory approval in the United States or internationally. Previously unknown adverse reactions resulting from human consumption of these ingredients could occur.

Our revenues are highly dependent on our private label distributors, which account for approximately 98 % of our revenues; our revenues could be reduced if any of these distributors reduce their orders from us or they cease using our services.

We receive approximately 98 % of our revenues from the sales made by our two private label distributors. As a result, our revenues are highly concentrated. Should these distributors decrease or cease-ordering products from us, our revenues and results of operations will be negatively affected.

Our insurance coverage may not be sufficient to cover our legal claims or other losses that we may incur in the future.

We maintain insurance, including property, general and product liability, and workers' compensation to protect ourselves against potential loss exposures. There is no assurance that our insurance will be sufficient to cover any claims that are asserted against us. In the future, insurance coverage may not be available at adequate levels or on adequate terms to cover potential losses, including on terms that meet our customer's requirements. If insurance coverage is inadequate or unavailable, we may face claims that exceed coverage limits or that are not covered,

which could increase our costs and adversely affect our operating results.

Our intellectual property rights are valuable, and any inability to protect them could reduce the value of our products and brand.

We have invested resources to protect our brands and intellectual property rights. However, we may be unable or unwilling to strictly enforce our intellectual property rights, including our trademarks, from infringement. Our failure to enforce our intellectual property rights could diminish the value of our brands and product offerings and harm our business and future growth prospects.

Adverse publicity or consumer perception of our products and any similar products distributed by others could harm our reputation and adversely affect our sales and revenues.

We believe we are highly dependent upon positive consumer perceptions of the safety and quality of our products as well as similar products distributed by other nutrition supplement companies. Consumer perception of nutrition supplements and our products in particular can be substantially influenced by scientific research or findings, national media attention and other publicity about product use. Adverse publicity from these sources regarding the safety, quality or efficacy of nutritional supplements and our products could harm our reputation and results of operations. The mere publication of news articles or reports asserting that such products may be harmful or questioning their efficacy could have a material adverse effect on our business, financial condition and results of operations, regardless of whether such news articles or reports are scientifically supported or whether the claimed harmful effects would be present at the dosages recommended for such products.

We may be subject to intellectual property rights claims, which are costly to defend, could require us to pay damages and could limit our ability to sell some of our products.

Our industry is characterized by vigorous pursuit and protection of intellectual property rights, which has resulted in protracted and expensive litigation for several companies. Third parties may assert claims of misappropriation of trade secrets or infringement of intellectual property rights against us or against our end customers or partners for which we may be liable.

As our business expands, the number of products and competitors in our markets increases and product overlaps occur, infringement claims may increase in number and significance. Intellectual property lawsuits are subject to inherent uncertainties due to the complexity of the technical issues involved, and we cannot be certain that we would be successful in defending ourselves against intellectual property claims. Further, many potential litigants have the capability to dedicate substantially greater resources than we can to enforce their intellectual property rights and to defend claims that may be brought against them. Furthermore, a successful claimant could secure a judgment that requires us to pay substantial damages or prevents us from distributing products or performing certain services.

If we fail to develop our brands cost-effectively, our business may be adversely affected.

The success of our products marketed under our brands will depend upon the effectiveness of our marketing efforts. Brand promotion activities may not yield increased revenue, and even if they do, any increased revenue may not offset the expenses incurred in building the brands. If we fail to successfully promote and maintain our brands, or incur substantial expenses in an unsuccessful attempt to promote and maintain our brands, we may fail to attract enough new customers or retain our existing customers to the extent necessary to realize a sufficient return on our brand-building efforts, and our business and results of operations could suffer.

The Diet and Nutritional Supplement industry is highly competitive, and our failure to compete effectively could adversely affect our market share, financial condition and future growth.

The diet and nutritional supplement industry is highly competitive with respect to price, brand and product recognition and new product introductions. Several of our competitors are larger, more established and possess greater financial, personnel, distribution and other resources. We face competition (1) in the health food channel from a limited number of large nationally known manufacturers, private label brands and many smaller manufacturers of dietary and nutrition supplements; and (2) in the mass-market distribution channel from manufacturers, major private label manufacturers and others. Private label brands at mass-market chains represent substantial sources of income for these merchants and the mass-market merchants often support their own labels at the expense of other brands. As such, the growth of our brands within food, drug, and general mass-market merchants is highly competitive and uncertain. If we cannot compete effectively, we may not be profitable.

We may experience greater than expected product returns, which might adversely affect our sales and results of operations.

Product returns are a customary part of our business. Products may be returned for various reasons, including expiration dates or lack of sufficient sales volume. Any increase in product returns could reduce our results of operations.

A shortage in the supply of key raw materials used by our manufacturer could increase our costs or adversely affect our sales and revenues.

Our inability to obtain adequate supplies of raw materials in a timely manner or a material increase in the price of the raw materials used in our products could have a material adverse effect on our business, financial condition and results of operations.

The purchase of many of our products is discretionary, and may be negatively impacted by adverse trends in the general economy and make it more difficult for us to generate revenues.

Our business is affected by general economic conditions since our products are discretionary and we depend, to a significant extent, upon a number of factors relating to discretionary consumer spending. These factors include economic conditions and perceptions of such conditions by consumers, employment rates, the level of consumers' disposable income, business conditions, interest rates, consumer debt levels and availability of credit. Consumer spending on our products may be adversely affected by changes in general economic conditions.

We may not be able to anticipate consumer preferences and trends within the diet and nutritional industry, which could negatively affect acceptance of our products by retailers and consumers and result in a significant decrease in our revenues.

The products sold under our NutraFuels brand name must appeal to a broad range of consumers, whose preferences cannot be predicted with certainty and are subject to rapid change. Products sold under the NutraFuels brand name will need to successfully meet constantly changing consumer demands. If our products are not successfully received by retailers and consumers, our business, financial condition, results of operations and prospects may be harmed.

The success of our business depends on our ability to market and advertise the products we sell effectively.

Our ability to establish effective marketing and advertising campaigns is the key to our success. Our advertisements

promote our corporate image, our dietary and nutritional products and the pricing of such products. If we are unable to increase awareness of our brands and our products, we may not be able to attract new customers. Our marketing activities may not be successful in promoting the products we sell or pricing strategies or in retaining and increasing our customer base. We cannot assure you that our marketing programs will be adequate to support our future growth, which may result in a material adverse effect on our results of operations.

Because we are subject to numerous laws and regulations we could incur substantial costs.

The manufacture, labeling and distribution of the nutritional and dietary products that we distribute is regulated by various federal, state and local agencies. These governmental authorities may commence regulatory or legal proceedings, which could restrict the permissible scope of our product claims or the ability to sell our products in the future. The FDA regulates our products to ensure that the products are not adulterated or misbranded.

Failure to comply with FDA requirements may result in, among other things, injunctions, product withdrawals, recalls, product seizures, fines and criminal prosecutions. Our advertising is subject to regulation by the FTC under the FTCA. In recent years the FTC has initiated numerous investigations of dietary and nutrition supplement products and companies. Additionally, some states also permit advertising and labeling laws to be enforced by private attorney generals, who may seek relief for consumers, seek class action certifications, seek class wide damages and product recalls of products sold by us. Any of these types of adverse actions against us by governmental authorities or private litigants could have a material adverse effect on our business, financial condition and results of operations.

Risks Related To Our Management

Should we lose the services of Edgar Ward, our founder, chief executive officer, president and sole director, our financial condition and proposed expansion may be negatively impacted.

Our future depends on the continued contributions of Edgar Ward, our founder, chief executive officer, president and sole director who would be difficult to replace. The services of Mr. Ward are critical to the management of our business and operations. We do not have an agreement with Mr. Ward obligating him to provide services to us. Additionally, we do not maintain key man life insurance on Mr. Ward. Should we lose the services of Mr. Ward and be unable to replace his services with equally competent and experienced personnel, our operational goals and strategies may be adversely affected, which will negatively affect our potential revenues.

Because we do not have an audit or compensation committee, shareholders will have to rely on the one member of our board of directors who is not independent to perform these functions.

We do not have an audit or compensation committee or board of directors as a whole that is composed of independent directors. These functions are performed by our sole director. Because our sole director is not independent, there is a potential conflict between their or our interests and our shareholders' interests since Edgar Ward, our sole board member is also our chief executive officer and president who will participate in discussions concerning management compensation and audit issues that may affect management decisions. Until we have an audit committee or independent directors, there may less oversight of management decisions and activities and little ability for minority shareholders to challenge or reverse those activities and decisions, even if they are not in the best interests of minority shareholders.

Our vice president devotes limited time to our business, which may negatively impact our plan of operations, implementation of our business plan and our potential profitability.

Neil Catania, our vice president currently devotes only 40 hours to our business each month. Our chief executive

officer and president, Edgar Ward devotes full time to our business; however, he is under no contractual obligation to do so and in the future he may spend limited time on our business. The limited amount of management time devoted to our business activities in the future may be inadequate to implement our plan of operations and develop a profitable business.

Risks Related to Our Common Stock

Our chief executive officer, president and sole director has voting control over all matters submitted to a vote of our common stockholders, which will prevent our minority shareholders from having the ability to control any of our corporate actions.

As of September 30, 2016 we had 30,768,628 shares of common stock outstanding, each entitled to one vote per common share. Our chief executive officer, president and sole director, Edgar Ward holds 6,103,385 common shares and 1,000 Series A Preferred Shares which provide him with 500,000 votes per share or an aggregate of 500,000,000 votes on all matters submitted to our stockholders. As a result, Mr. Ward has the ability to determine the outcome of all matters submitted to our stockholders for approval, including the election of directors. Mr. Ward's control of our voting securities may make it impossible to complete some corporate transactions without his support and may prevent a change in our control. In addition, this ownership could discourage the acquisition of our common stock by potential investors and could have an anti-takeover effect, possibly depressing the trading price of our common stock.

We are obligated to issue additional common shares to investors upon the conversion of outstanding notes, warrants and options, which would reduce investors' percent of ownership and may dilute our share value.

We have the following convertible securities outstanding:

- promissory notes with aggregate principal and interest outstanding as of September 30, 2016 of $2,369,698 which are convertible into an aggregate of 2,076,939 common shares,
- options convertible into an aggregate of 275,000 common shares, and
- warrants convertible into an aggregate of 7,682,000 common shares.

The issuance of the shares in the future upon conversion of these securities will result in substantial dilution in the percentage of our common stock held by our existing shareholders. Any securities sold more than twelve months prior to the date hereof are currently eligible for resale under Rule 144. In general, persons holding restricted securities in a company not reporting with the Securities & Exchange Commission, including affiliates, must hold their shares for a period of at least twelve months. Additionally, affiliates may not sell more than one percent of the total issued and outstanding shares in any 90-day period, and must resell the shares in an unsolicited brokerage transaction at the market price. If substantial amounts of our common stock are resold under Rule 144, prevailing market prices for our common stock will be reduced.

We may, in the future, issue additional securities which would reduce investors' percent of ownership and may dilute our share value.

Our Articles of Incorporation authorize us to issue 499,990,000 shares of common stock. As of September 30, 2016, we had 30,768,628 shares of common stock outstanding. Accordingly, we may issue up to an additional 469,221,372

shares of common stock. The future issuance of common stock may result in substantial dilution in the percentage of our common stock held by our then existing shareholders. We may value any common stock issued in the future on an arbitrary basis including for services or acquisitions or other corporate actions that may have the effect of diluting the value of the shares held by our stockholders, and might have an adverse effect on any trading market for our common stock. Additionally, we are authorized to issue 10,000 shares of preferred stock of which 1,000 shares are outstanding. As such, we may issue an additional 9,000 shares of preferred stock. Our board of directors may designate the rights, terms and preferences of our authorized but unissued preferred shares at its discretion including conversion and voting preferences without notice to our shareholders.

Describe the Issuer's Facilities

We lease an aggregate of 6,400 square feet of office and warehouse space at 6601 Lyons Rd, Suites L-6&7, Coconut Creek, FL 33073, with base rent at $5,300 per month from Lyons Corporate Park for our executive offices and manufacturing facility. Approximately 5,800 square feet is used for manufacturing and distribution. The lease term expires on December 31, 2018. We believe our facilities are suitable for our present needs. Other than the foregoing, we do not intend to renovate, improve, or develop properties.

Officers, Directors, and Control Persons

The names of each of our executive officers, directors, general partners and control persons (control persons are beneficial owners of more than ten percent (10%) of any class of the issuer's equity securities), as of the date of this information statement.

The following tables set forth the ownership of our common stock by each person known by us to be the beneficial owner of more than ten percent (10%) of our outstanding common stock, our directors, and our executive officers as a group as of September 9, 2016. To the best of our knowledge, the persons named have sole voting and investment power with respect to such shares, except as otherwise noted. There are not any pending or anticipated arrangements that may cause a change in control.

The information presented below regarding beneficial ownership of our voting securities has been presented in accordance with the rules of the Securities and Exchange Commission and is not necessarily indicative of ownership for any other purpose. Under these rules, a person is deemed to be a "beneficial owner" of a security if that person has or shares the power to vote or direct the voting of the security or the power to dispose or direct the disposition of the security. A person is deemed to own beneficially any security as to which such person has the right to acquire sole or shared voting or investment power within 60 days through the conversion or exercise of any convertible security, warrant, option or other right. More than one person may be deemed to be a beneficial owner of the same securities. The percentage of beneficial ownership by any person as of a particular date is calculated by dividing the number of shares beneficially owned by such person, which includes the number of shares as to which such person has the right to acquire voting or investment power within 60 days, by the sum of the number of shares outstanding as of such date. Consequently, the denominator used for calculating such percentage may be different for each beneficial owner. Except as otherwise indicated below and under applicable community property laws, we believe that the beneficial owners of our common stock listed below have sole voting and investment power with respect to the shares shown. The business address of the shareholders is 6601 Lyons Road, L 6 Coconut Creek, FL 33073.

Class	Position	Amount Beneficial Ownership (1)	Direct Ownership	Indirect Ownership	Percent of Class
COMMON	Edgar Ward (2) Chief Executive Officer, Director	6,103,385	6,103,385	0	19.76%
COMMON	Neil Catania (3) Vice - President	4,133,691	4,133,691	0	13.38%
COMMON	**All officers and directors as a Group (2 persons)**	10,237,076	10,237,076	0	33.14.%
SERIES A PREFERRED SHARES	Edgar Ward (2) Chief Executive Officer	1,000	1,000	0	100%
SERIES A PREFERRED SHARES	Neil Catania Vice-President	0	0	0	0%
SERIES A PREFERRED SHARES	**All officers and directors as a Group (2 persons)**	1,000	1,000	0	100%

(1) Based upon 30,893,628 common shares outstanding as of September 9, 2016.
(2) As a result of Mr. Ward's ownership of 6,103,385 common shares and 1,000 Series A Preferred Shares he holds 95% of the votes on all matters submitted to a vote of our stockholders.
(3) The amount reflected for Neil Catania includes 3,403,571 shares held directly and 730,120 shares issuable upon conversion of outstanding Promissory Notes that have an aggregate amount of principal and interest due of $730,120 and which are convertible at the per share price of $1.00 per share.

B. Legal/Disciplinary History.

None of the Company's officers, directors or control persons have, in the last ten years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

3. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

C. Beneficial Shareholders.

Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

Legal Counsel
Name: Brenda Hamilton, Attorney
Firm: Hamilton & Associates Law Group, P.A.
Address 1: 101 Plaza Real South, Suite 202 North
Address 2: Boca Raton Florida 33432
Phone: 561-416-8956
Email: BHamilton@securitieslawyer101.com
Website: www.securitieslawyer101.com

Durland & Co
PO Box 49671
Greensboro, NC 27419
Telephone 561-253-4518
Facsimile 336-265-8147

Issuer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

The certifications shall follow the format

below: I, Edgar Ward certify that:

1. I have reviewed this Annual Information and Disclosure Statement of NutraFuels, Inc.

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Edgar Ward
By: Edgar Ward,

President

Dated

December 2, 2016